Hemorrhagic Shock Clinical Trial
— TRFLOfficial title:
Formula-driven vs Laboratory-guided Transfusion Practices in Bleeding Trauma Patients: A Feasibility Randomized Controlled Study
Background: Bleeding and coagulopathy still accounts for the majority of early in-hospital
deaths following trauma. There have been lately several published studies suggesting that
higher transfusion ratios of fresh frozen plasma (FFP), platelets (PTL) and cryoprecipitate
(CRYO) to red blood cell (RBC) are associated with survival advantages. However, the
evidence comes from retrospective data limited by a significant number of unaddressed
confounders. In addition, the use of blood products bears known and important risks of
complications.
Hypothesis: The adoption of a formula-driven transfusion practice with pre-defined ratios of
FFP to PTL to RBC transfusion (1:1:1) is feasible and superior to current laboratory-guided
transfusion practice in treating and/or preventing early coagulopathy improving survival
rates in massively bleeding trauma patients .
Objective: To exam the feasibility of implementing a pre-defined ratio of FFP to PTL to RBC
(1:1:1) transfusion protocol and its impact on a population of bleeding trauma patients.
Design: A two-year pilot feasibility randomized control trial at Sunnybrook Health Sciences
Centre. Randomization: 70 patients are expected to be randomized to lab-driven or to
formula-driven massive transfusion protocol and followed-up to 28 days or hospital
discharge.
Study outcomes: protocol violation; in-hospital mortality by exsanguination; death at 28
days; coagulation competence defined by current standard coagulation tests (INR & PTT < 1.5
times normal; PTL ≥ 50 and Fibrinogen ≥ 1.0) or clotting factor levels ≥ 30%; correlation of
current standard coagulation tests with clotting factors levels; cessation of bleeding;
incidence of ALI, sepsis, MOF, transfusion-related circulatory overload, transfusion
reactions; Ventilator-free days; ICU & Hospital LOS; thromboembolic events.
Intervention protocol: Transfusion of pre-defined ratios of FFP and PTL to RBC (1:1:1)
(formula-driven) for the first 12h of hospitalization without coagulation tests guidance
while patient is hemorrhaging or before if bleeding stops.
Statistical analysis: protocol compliance rate and in-hospital mortality rates within 24h
and at 28 days will be assessed using Chi-square test. ROC analysis will be used to analyze
coagulation competence.
Main expected outcomes: implementation of a formula-driven transfusion protocol is feasible
and coagulation competence will be achieved faster and more efficiently in the study group.
Status | Completed |
Enrollment | 70 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria Patients were eligible for this study if they: i) were adult trauma patients assessed by the trauma team; and ii) suffered either penetrating or blunt mechanism of injury; and 1. were bleeding and expected to require massive transfusion (either 4 units within the next 2 hours or = 10 units of RBC in 24 h) or required transfusion of un-cross matched emergency stock red blood cells; and 2. had an episode of hypotension (systolic bp = 90mmHg). Exclusion Criteria Patients were excluded if: i) they were assessed in the trauma room more than six hours after injury; or ii) they received more than two units of RBC transfusion prior to arrival; or iii) they had suffered a concomitant severe brain injury (defined as any of the following: Glasgow Coma Scale of 3 due to severe traumatic brain injury; clear indication of immediate neurosurgical intervention based on clinical findings, mechanism of trauma associated with focal signs (anisocoria, CT evidence of intracranial bleeding with mass effect); or iv) they had evidence of having a catastrophic head injury (such as transcranial gunshot wound, open skull fracture with exposure/loss of brain tissue, or expert opinion by either the trauma team leader or neurosurgical consultant based on initial clinical or initial CT findings); or v) they had evidence that their shock state was unrelated to hemorrhage (ie cardiogenic, septic, anaphylactic, acute adrenal insufficiency, neurogenic, or obstructive (cardiac tamponade, tension pneumothorax and massive pulmonary emboli); or vi) they had a known hereditary or acquired coagulopathy unrelated to the trauma resuscitation (for example: hemophilia, hepatic insufficiency, or anti-coagulant medications); or vii) they were moribund with evidence of unsalvageable injuries. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Sunnybrook Health Sciences Centre | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Sunnybrook Health Sciences Centre | Canadian Blood Services, Canadian Department of National Defense, National Blood Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Protocol compliance | 12 hours | No | |
Secondary | Mortality by Exsanguination; Hospital mortality; Cessation of Bleeding; Coagulation competence; Multiple Organ Dysfunction; Transfusion complications. | early and at 28 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04149171 -
Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage
|
Phase 3 | |
Not yet recruiting |
NCT06070350 -
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
|
Phase 3 | |
Not yet recruiting |
NCT02880163 -
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
|
N/A | |
Completed |
NCT02924792 -
Sternal Intraosseous Transfusion of Autologous Whole Blood: A Comparison of Flow Rates and Degree of Hemolysis
|
N/A | |
Terminated |
NCT00750997 -
Hypertonic Modulation of Inflammation Following Injury
|
N/A | |
Terminated |
NCT03477006 -
Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial
|
Phase 3 | |
Not yet recruiting |
NCT04987411 -
Detection of Exhaled Methane Levels in Hemorrhagic Shock
|
||
Recruiting |
NCT04610814 -
Blood Transfusion by Boston MedFlight Registry
|
||
Completed |
NCT02071290 -
Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock
|
N/A | |
Completed |
NCT03535441 -
HMGB1 Release From Hemorrhagic Shock Patients
|
||
Completed |
NCT03480555 -
Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients
|
N/A | |
Completed |
NCT03402035 -
Shock, Whole Blood, and Assessment of TBI S.W.A.T. (LITES TO 2)
|
||
Completed |
NCT05081063 -
Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
|
Phase 3 | |
Recruiting |
NCT03235921 -
Use of Nitroglycerine to Improve Signs of Poor Peripheral Perfusion in Patients With Traumatic Hemorrhagic Shock
|
Phase 2 | |
Active, not recruiting |
NCT03469947 -
California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA
|
Phase 3 | |
Completed |
NCT01411852 -
Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma
|
Phase 2 | |
Withdrawn |
NCT01221389 -
Study Using Plasma for Patients Requiring Emergency Surgery
|
Phase 4 | |
Recruiting |
NCT03406598 -
Bedside Visual Analysis of Sublingual Microcirculation in Shock Patients
|
||
Completed |
NCT00328133 -
The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry
|
N/A | |
Completed |
NCT00379522 -
Vasopressin in Traumatic Hemorrhagic Shock Study
|
Phase 2/Phase 3 |